ReviewNutrients2019
Obesity in the Liver Transplant Setting.
Review in Nutrients, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- The role of preoperative optimization of the nutritional status on the improvement of short-term outcomes after liver transplantation? A review of the literature and expert panel recommendations.Clinical transplantation · 2022Pooled it
- Self-reported poor quality of sleep in solid organ transplant: A systematic review.Transplantation reviews (Orlando, Fla.) · 2021Pooled it
- Liver transplantation and bariatric surgery: a new surgical reality: a systematic review of the best time for bariatric surgery.Updates in surgery · 2021Pooled it
- Feasibility, Acceptability, and Satisfaction of a Lifestyle Intervention for Post-Transplant Weight Loss.Transplantation proceedings · 2025Trial
- Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.The lancet. Gastroenterology & hepatology · 2023Trial
- Consensus statement on obesity management in liver transplantation candidates.Updates in surgery · 2026Article
- A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States.PharmacoEconomics · 2026Article
- Dietary habits among solid organ transplant recipients: results from a single-center study in Poland.Frontiers in nutrition · 2026Article
- TASL practice guidance for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease (MASLD).Hepatology forum · 2026Article
- Nutritional aspects of prehabilitation in adults with cirrhosis awaiting liver transplant.Hepatology (Baltimore, Md.) · 2025Review
- A review of multidisciplinary care in metabolic dysfunction-associated steatohepatitis and cardiometabolic disease, with a focus on Canada.Diabetes, obesity & metabolism · 2025Review
- Synergistic Integration of Multimodal Metabolic and Bariatric Interventions Transforming Transplant Care.Journal of clinical medicine · 2025Review
- Article
- Obesity-associated Inflammation and Alloimmunity.Transplantation · 2025Review
- Ethical frontiers in liver transplantation.World journal of transplantation · 2024Review
- Mental and Physical Readiness for Weight Loss After Abdominal Organ Transplant.The Journal of surgical research · 2024Article
- A real-world disproportionality analysis of semaglutide: Post-marketing pharmacovigilance data.Journal of diabetes investigation · 2024Article
- Monocentric, Retrospective Study on Infectious Complications within One Year after Solid-Organ Transplantation at a Belgian University Hospital.Microorganisms · 2024Article
- New Developments and Challenges in Liver Transplantation.Journal of clinical medicine · 2023Review
- Obesity management for the pre-liver transplant and post-liver transplant patient.Clinical liver disease · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The obesity epidemic has resulted in an increased prevalence of obesity in liver transplant (LT) candidates and in non-alcoholic fatty liver disease (NAFLD) becoming the fastest growing indication for LT. LT teams will be dealing with obesity in the coming years, and it is necessary for them to recognize some key aspects surrounding the LT in obese patients. Obesity by itself should not be considered a contraindication for LT, but it should make LT teams pay special attention to cardiovascular risk assessment, in order to properly select candidates for LT. Obese patients may be at increased risk of perioperative respiratory and infectious complications, and it is necessary to establish preventive strategies. Data on patient and graft survival after LT are controversial and scarce, especially for long-term outcomes, but morbid obesity may adversely affect these outcomes, particularly in NAFLD. The backbone of obesity treatment should be diet and exercise, whilst being careful not to precipitate or worsen frailty and sarcopenia. Bariatric surgery is an alternative for treatment of obesity, and the ideal timing regarding LT is still unknown. Sleeve gastrectomy is probably the procedure that has the best evidence in LT because it offers a good balance between safety and efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.